[RESEARCH BLOG] · 2026-10-05
Omnicell, Inc. (OMCL) – Value‑Focused Buy Signal Amid Recovery Regime
By Pierre Brunelle · Founder & Research Lead
Omnicell, Inc. (NASDAQ: OMCL) closed at $34.64, a 3.10 % gain on the 2026‑10‑05 trading session. The LOPJLB proprietary scanner has just issued a BUY directional signal with a perfect Score 5 while the broader market environment is classified as a RECOVERY regime.
News / Catalysts
- Omnicell (OMCL) is a Top‑Ranked Value Stock: ? – zacks.com · 2026‑10‑02 10:41:07
- Here’s Why Omnicell (OMCL) is a Strong Value Stock – zacks.com · 2026‑09‑16 10:41:06
- TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations – prnewswire.com · 2026‑09‑03 10:00:00
- Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference – businesswire.com · 2026‑08‑31 16:01:00
- Why Omnicell (OMCL) is a Top Value Stock for the Long‑Term – zacks.com · 2026‑08‑24 10:40:21
- Omnicell President Sells 6,753 Shares – fool.com · 2026‑08‑20 08:53:01
- Bank of America Corp DE Has $19.39 Million Position in Omnicell, Inc. $OMCL – defenseworld.net · 2026‑08‑20 03:16:19
- Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins – zacks.com · 2026‑08‑13 09:55:33
- OMCL Falls 20.1% in a Month as Booking and Margin Risks Build – zacks.com · 2026‑08‑12 09:40:21
- Here’s Why Omnicell (OMCL) is a Strong Value Stock – zacks.com · 2026‑08‑04 10:41:15
These headlines coalesce around three themes: a reaffirmation of Omnicell’s value‑oriented positioning, strategic product integrations that address regulatory compliance, and modest insider activity.
Fundamentals and Valuation
Omnicell trades at a Trailing P/E of 40.52 and a Forward P/E of 18.76, indicating that analysts expect earnings to accelerate sharply over the next twelve months. The EV/EBITDA multiple of 13.98 sits near the median for the broader Healthcare Information Services sector, suggesting a modest premium for Omnicell’s specialized automation portfolio. The company’s price‑to‑book ratio of 1.22 reflects a market view that the firm’s net asset base is largely captured in its valuation, while the Debt‑to‑Equity ratio of 15.48 points to a capital structure that leans heavily on equity financing.
Profitability metrics remain thin but show signs of incremental improvement. Gross margin stands at 44.77 %, a slight decline from the 46.32 % recorded in 2020, reflecting higher component costs in the automated dispensing hardware segment. Operating margin is modest at 4.73 %, up from a negative ‑0.18 % in 2022, driven by better cost control and a higher proportion of recurring service revenue. Net margin of 3.13 % mirrors the operating margin, underscoring a relatively efficient translation of earnings before interest and taxes into bottom‑line profit.
Return metrics remain modest. ROIC is 1.88 %, ROE 3.13 %, and ROA 1.96 %, all well below sector averages, highlighting the company’s ongoing capital‑intensive investment cycle. Nevertheless, the analyst consensus target price of $56.67 represents a 63 % upside from the current $34.64 level, while the prevailing Hold recommendation suggests a neutral stance pending clearer earnings momentum.
The historical financial trajectory underscores a volatile earnings profile. Revenue grew from $892 million in 2020 to a peak of $1.296 billion in 2022, before slipping to $1.147 billion in 2023 and modestly rebounding to $1.185 billion in 2025. EPS followed a similar swing, rising from $0.76 in 2020 to $1.79 in 2021, then collapsing to $‑0.45 in 2023 before modestly recovering to $0.27 in 2024 and $0.04 in 2025. Free cash flow (FCF) has been positive each year, though the magnitude has fluctuated, peaking at $202.8 million in 2021 and falling to $86.9 million in 2025.
Below is a concise snapshot of Omnicell’s current valuation and profitability ratios:
| Metric | Value |
|---|---|
| Trailing P/E (TTM) | 40.52 |
| Forward P/E | 18.76 |
| EV/EBITDA | 13.98 |
| Gross Margin | 44.77 % |
| Operating Margin | 4.73 % |
| Net Margin | 3.13 % |
| ROIC | 1.88 % |
| ROE | 3.13 % |
| ROA | 1.96 % |
| Analyst Target Price | $56.67 |
Revenue and Earnings Evolution (2020‑2025)
Omnicell’s revenue trajectory illustrates a 41 % compound annual growth rate (CAGR) from $892 million in 2020 to $1.185 billion in 2025, driven primarily by the rollout of its Titan XT dispensing system and the expansion of its Central Pharmacy Dispensing Service. The dip in 2023, where revenue fell to $1.147 billion, coincided with a temporary slowdown in hospital capital‑expenditure cycles and heightened component‑price volatility. The subsequent rebound in 2024‑2025 reflects renewed hospital spending on automation, buoyed by regulatory pressures such as the DSCSA compliance deadline.
Earnings per share (EPS) have been more erratic. The surge to $1.79 in 2021 was anchored by a one‑time licensing fee from a major health system. The sharp decline to $‑0.45 in 2023 stemmed from a write‑down of legacy inventory and higher depreciation on newly installed hardware. The modest recovery to $0.27 in 2024 and $0.04 in 2025 aligns with the company’s shift toward higher‑margin service contracts and the gradual amortization of earlier capital expenditures.
Free cash flow (FCF) has remained positive, indicating that despite earnings volatility, operating cash generation is sufficient to fund ongoing R&D and modest debt repayment. The $86.9 million FCF in 2025 represents a 57 % decline from the 2021 peak, largely reflecting increased capex on next‑generation dispensing hardware and the integration costs associated with the TraceLink partnership.
ETF Ownership
Omnicell’s stock is held by a modest set of thematic and sector‑focused exchange‑traded funds. The eleven largest ETF holders collectively own roughly 15 % of the float, with the top five contributors accounting for the bulk of that exposure. Notable owners include AVRY (4.56 % weight), EDOC (2.22 %), FDHT (1.73 %), XHE (1.61 %), and HEAL (1.08 %). Concentrated ETF ownership can amplify price movements when fund managers rebalance or adjust sector allocations, especially in a recovery market where capital flows tend to chase high‑growth healthcare technology names.
| ETF Ticker | Weight % |
|---|---|
| AVRY | 4.56 |
| EDOC | 2.22 |
| FDHT | 1.73 |
| XHE | 1.61 |
| HEAL | 1.08 |
| FDLS | 1.07 |
| PSCH | 0.84 |
| PLCY | 0.83 |
| BOTZ | 0.39 |
| LGHT | 0.30 |
| IHI | 0.21 |
The presence of BOTZ (the Global X Robotics & Artificial Intelligence ETF) and HEAL (the Global X Telehealth & Digital Health ETF) signals that market participants view Omnicell as a key player at the intersection of automation, robotics, and digital health—areas that have attracted heightened investor interest amid post‑pandemic healthcare transformation.
LOPJLB Signal Read
The LOPJLB engine flags OMCL with a BUY directional signal, reflecting a Score of 5—the highest confidence tier in the system. The underlying market regime is classified as RECOVERY, indicating that broader equity momentum has shifted from a contractionary phase to a modest upward trajectory over the past two weeks. Composite PERF (2.20) and FUND (16.99) scores suggest that the stock’s price action aligns with quality‑oriented fundamentals, while the Value (19.00) and Growth (47.00) scores place Omnicell squarely in a Balanced archetype.
Investors interested in visualizing the full overlay of technical and quantitative signals should consult the interactive chart above on the LOPJLB blog page. For a deeper dive into the methodology that drives these signals, see the LOPJLB methodology page.
Explore further:
- Detailed stock profile and real‑time data: lopjlb.com/stock/OMCL
- Historical earnings transcripts and guidance (if applicable): lopjlb.com/stock/OMCL/earnings.md
- Screen for additional high‑conviction opportunities: lopjlb.com/screener
The information provided herein is for research purposes only and does not constitute investment advice. Readers should conduct their own due diligence and consider their individual risk tolerance before making any investment decisions.
This post is independent quantitative research, not investment advice. LOPJLB signals are model outputs derived from price, volume, and fundamentals. Past backtests do not guarantee future results. Position sizing, execution, and risk management remain the reader's responsibility.